Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study to Evaluate the Clinical Efficacy and Safety of Sintilimab Plus Low-dose Bevacizumab in Patients With Glioblastoma of Different Relapse Stages

NCT05502991 is registered in ClinicalTrials.gov with Henan Provincial People's Hospital as lead sponsor.

NCT NCT05502991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05502991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study to Evaluate the Clinical Efficacy and Safety of Sintilimab Plus Low-dose Bevacizumab in Patients With Glioblastoma of Different Relapse Stages
Lead sponsor
Henan Provincial People's Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 11, 2022
Completion date
December 31, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma